Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5087108 | 0.98 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| Water SCHEMBL11129746 | 0.98 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| Iodide SCHEMBL5091725 | 0.98 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| Bromide SCHEMBL5088285 | 0.98 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| SCHEMBL114846 | 0.82 | KCNN4 (0.44) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| SCHEMBL10435748 | 0.82 | TRPM8 (0.43) | ALDH1A1KIF11 | |
| SCHEMBL14944876 | 0.80 | CYP1A2 (0.42) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| SCHEMBL6741619 | 0.78 | TAAR1 (0.41) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A | |
| SCHEMBL10435750 | 0.77 | ALOX5 (0.54) | CYP1A2LMNAHIF1AALOX5 | |
| SCHEMBL114847 | 0.76 | KCNN4 (0.48) | KCNN4CYP1A2CYP2D6TAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-7141674-B2 | Anti-inflammatory compounds | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1201649-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1201660-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014741-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | KCNN4 4196/4885CYP1A2 217/4885CYP2D6 400/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | KCNN4 4173/4885CYP1A2 214/4885CYP2D6 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.